Influenza Diagnostics Market Overview:
The Influenza Diagnostics Market is expected to grow at a 7.7% CAGR from USD 0.8 billion in 2021 to USD 1.1 billion in 2026. Rising demand for rapid disease diagnosis, rising influenza prevalence, and increased influenza research for diagnostic tecahnologies are driving market expansion.The global influenza diagnostics market is expected to grow at a CAGR of 7.7% over the forecast period, from USD 0.8 billion in 2021 to USD 1.1 billion in 2026. The rising prevalence of influenza, growth in influenza research for diagnostic technologies, and rising demand for rapid disease detection are all driving growth in the influenza diagnostics market. However, variations in test sensitivity and specificity, as well as rising healthcare expenses, are limiting the market's expansion.
COVID-19 Impact on Global Influenza Diagnostics Market
The emergence of the COVID-19 pandemic has changed the delivery of medical care across the world. The COVID-19 pandemic has significantly affected the influenza diagnostics market; unfavorable changes in regulations and guidelines, the closing of manufacturing facilities due to lockdowns and disruptions in supply chains have severely affected the market growth. In addition, limited operations in most industries, inadequate funding for research and academic institutes, and challenges in providing essential/post-sales services due to lockdowns have reduced the supply of influenza diagnostics products to end users. Furthermore, there are many similarities between influenza and COVID-19; both seasonal flu (influenza A and B) and COVID-19 are contagious viruses and show similar symptoms of respiratory illness. Influenza outbreaks generally occur from December to February. The COVID-19 outbreak also occurred during the influenza season, resulting in the increased adoption of influenza tests during this period.
Request For Sample:
In 2020, molecular diagnostic tests segment accounted for the largest share of the influenza diagnostics market, by test type
The influenza diagnostics market is segmented into molecular diagnostics tests and traditional diagnostic tests based on test type. In 2020, the molecular diagnostic tests segment accounted for the largest share. Factors such as growth in influenza research for diagnostic technologies and increasing prevalence of influenza drive this market.
In 2020, diagnostic laboratories segment accounted for the largest share in the influenza diagnostics market, by end users
The influenza diagnostics market has been segmented into diagnostic laboratories, hospitals and clinics and other end users based on end users. In 2020, the diagnostic laboratories segment accounted for the largest share of the influenza diagnostics market. Increasing prevalence of influenza and rising demand for rapid disease diagnosis is driving the growth of this segment.
Molecular Diagnostic Tests segment to register the highest growth rate during the forecast period
The influenza diagnostics market is segmented into traditional diagnostic test (rapid influenza diagnostic tests, viral culture tests, direct fluorescent antibody test, serological tests) and molecular diagnostic tests (polymerase chain reaction, isothermal nucleic acid amplification tests(transcription-mediated amplification-based assay, loop-mediated isothermal amplification-based assay, nucleic acid sequence-based amplification tests, other isothermal nucleic acid amplification tests) and other molecular diagnostic tests. In 2020, the molecular diagnostic tests segment accounted for the highest growth rate. Factors such as the rising demand for rapid disease diagnosis drive this market and growth in influenza research for diagnostic technologies.
The major players in this market are Danaher Corporation (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), F. Hoffmann-LA Roche AG (Switzerland), Abbott Laboratories, Inc. (Us), Hologic, Inc. (US), bioMérieux SA (France), Quidel Corporation (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), GenMark Diagnostics, Inc. (US), Luminex Corporation (US), Tecan Trading AG (Switzerland), DiaSorin SA (Italy), altona Diagnostics GmbH (Germany), SEKISUI Diagnostics (US), SA Scientific Ltd. (US), Coris BioConcept SPRL (Belgium), ELITech Group (France), Mast Group Ltd. (UK), Genome Diagnostics, Pvt. Ltd. (India), Germaine Laboratories, Inc. (US), Response Biomedical Corp. (Canada). Tauns Laboratories, Inc. (Japan) and 3B BlackBio Biotech India Ltd. (India)
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model — GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1–888–600–6441